Development of Drugs for Resistant Organisms Presentation to FDA Anti-Infective Drugs Advisory Committee March 5, 2003

Jan 26, 2013

240 likes | 461 Views

Development of Drugs for Resistant Pathogens Characteristics to Justify Development. Microbiological SuperiorityInhibit resistant organismsPharmacological AdvantageFrequency of dosingEase of administrationSafety Advantage. Development of Drugs for Resistant Pathogens Preclinical IND Criteria.

Share Presentation

Embed Code

Link

hoang

Download Presentation

Development of Drugs for Resistant Organisms Presentation to FDA Anti-Infective Drugs Advisory Committee March 5, 2003

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

FDA Oncologic Drugs Advisory Committee Pediatric Oncology Subcommittee

FDA Oncologic Drugs Advisory Committee Pediatric Oncology Subcommittee. Endpoints for New Drugs to Treat Pediatric Brain Tumors 6 December 2006. Report on. Public Workshop on Brain Tumor Clinical Trials Endpoints. 20 January 2006. Sponsored by FDA – AACR – ASCO . Larry E. Kun, MD

665 views • 37 slides

FDA Medical Imaging Drugs Advisory Committee

FDA Medical Imaging Drugs Advisory Committee. July 10, 2000 BLA 99-1407 LeuTech ® Palatin Technologies, Inc. CP000.02. CP001.01. Palatin Presenters. Charles Putnam Chief Operating Officer Palatin Technologies, Inc.

1.26k views • 92 slides

Anti-Infective Drugs Advisory Committee Meeting Clinical Trial Designs for Community Acquired Pneumonia

Anti-Infective Drugs Advisory Committee Meeting Clinical Trial Designs for Community Acquired Pneumonia. April 1 & 2, 2008 Edward Cox, MD MPH Director, Office of Antimicrobial Products OND/CDER/FDA. Welcome. Welcome Topic for discussion

4.36k views • 370 slides

Arthritis Advisory Committee March 5, 2003

Arthritis Advisory Committee March 5, 2003. Lee S. Simon, MD Division Director Analgesic, Anti-inflammatory, Ophthalmologic Drug Products HFD-550/CDER/FDA. Agenda. Regulatory history of Arava in the context of therapy for Rheumatoid arthritis

654 views • 39 slides

DOSE SELECTION FOR ANTI-INFECTIVE DRUGS: INDUSTRY PERSPECTIVE

DOSE SELECTION FOR ANTI-INFECTIVE DRUGS: INDUSTRY PERSPECTIVE. Dennis M. Grasela, PharmD, PhD Executive Director, Infectious Diseases Department of Clinical Discovery Bristol-Myers Squibb Pharmaceutical Research Institute FDA/IDSA/ISAP Workshop 15-16 April 2004. OUTLINE.

444 views • 21 slides

FDA Anesthetic & Life Support Drugs Advisory Committee Sept. 10, 2003

FDA Anesthetic & Life Support Drugs Advisory Committee Sept. 10, 2003. Art Van Zee,MD St. Charles Clinic St. Charles, Va. Susstained-release hydromorphone (Palladone) --Risks vs. benefits discussion. Benefits Review sustained release opioids vs. IR opioids.

387 views • 22 slides

Anti-infective Drugs

Anti-infective Drugs. Jan Bazner-Chandler MSN, CNS, RN, CPNP. Bacteria . Bacteria. Gram-positive bacterium has a thick layer of peptioglycan. Gram-negative bacterium has a thin peptioglycan layer and an outer membrane. Common Bacterial Pathogens. Gram positive Staphylococcus aureus

1.69k views • 85 slides

Update on Congenital Eye Malformations Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting J

Update on Congenital Eye Malformations Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004. Solomon Iyasu, MD, MPH Medical Team Leader Division of Pediatric Drug Development Center for Drug Evaluation and Research Food and Drug Administration.

333 views • 10 slides

Presented by Carl Norden, M.D. at the Anti-Infective Drugs Advisory Committee meeting on October 28, 2003

Presented by Carl Norden, M.D. at the Anti-Infective Drugs Advisory Committee meeting on October 28, 2003. DFI Clinical Trial. Differs from cSSSI trial Risk factors (vascular, neuropathy, diabetes itself) Adjunctive therapy Debridement and surgery are integral Wound care Off-loading.

357 views • 22 slides

III.6. Anti-infective Drugs

III.6. Anti-infective Drugs. Salvarsan and Prontosil.

261 views • 13 slides

FDA Anti-Infective Drugs Advisory Committee, October 2003

Diabetic foot infection: what remains to be discovered?. Dr. Tony Berendt, BM, BCh, FRCP Bone Infection Unit, Oxford. FDA Anti-Infective Drugs Advisory Committee, October 2003. Take home messages. Despite considerable advances, there is much we do not know about diabetic foot infection

875 views • 40 slides

Joint Meeting of the Anti-Infective Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee

Causality Assessment for Drug- Induced Liver Injury Leonard B. Seeff, M.D. NIDDK, NIH. Joint Meeting of the Anti-Infective Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee Silver Spring, Maryland December 14-15, 2006.

352 views • 31 slides

FDA Advisory Committee March 6, 2003

An Unmet Medical Need. Prevention of Chemotherapy-Induced Nausea and Vomiting. Over one million cancer patients receive chemotherapy each year20% highly emetogenic chemotherapy (HEC)Chemotherapy-induced nausea and vomiting (CINV)Among the most distressing side effects of chemotherapyDisrupt pati

1.67k views • 145 slides

Antiviral Drugs Advisory Committee Meeting

Antiviral Drugs Advisory Committee Meeting. Raltegravir NDA 22-145 September 5, 2007. NDA 22-145 : Isentress™ (raltegravir potassium) Applicant : Merck & Co., Inc. Formulation : 400 mg tablets Indication : HIV-1 treatment-experienced adult patients.

348 views • 10 slides

Ant-Infective Drugs

Ant-Infective Drugs. Antibacterials Sulfa Drugs Urinary Anti-tuberculosis Antifungals Antivirals. Antibacterial Drugs (Antibiotics & Antimicrobials). I. Increased Susceptibility to Infection A. Age B. Exposure C. Barrier Disruption D. Immune Defenses E. Circulation

1.17k views • 22 slides

Presented by Carl Norden, M.D. at the Anti-Infective Drugs Advisory Committee

Presented by Carl Norden, M.D. at the Anti-Infective Drugs Advisory Committee meeting on October 28, 2003. Study Exclusion Criteria - 1. General conditions Pregnant/breast-feeding women Hypersensitivity to any of the main study antibiotics Absolute neutrophil count <500/mm 3

285 views • 15 slides

FDA Endocrine and Metabolic Drugs Advisory Committee October 7, 2003

FDA Endocrine and Metabolic Drugs Advisory Committee October 7, 2003. Joseph S. Camardo, M.D. Senior Vice President Clinical Research. Agenda. Introduction and Overview: Use of estrogen/progestin for osteoporosis The clinical data for estrogen/progestin The WHI data and clinical practice

497 views • 36 slides

FDA Advisory Committee for Pharmaceutical Science—March 13, 2003

FDA Advisory Committee for Pharmaceutical Science—March 13, 2003. Carlos R. Hamilton, Jr. MD, FACE American Association of Clinical Endocrinologists—Vice President The University of Texas Health Science Center—Houston, Executive Vice-President for Clinical Affairs .

215 views • 7 slides

Development of Drugs for Resistant Pathogens

Development of Drugs for Resistant Pathogens. Francis P. Tally M.D. Cubist Pharmaceuticals, Inc. Development of Drugs for Resistant Pathogens. Antimicrobials Developed. Development of Drugs for Resistant Pathogens Characteristics to Justify Development. Microbiological Superiority

391 views • 28 slides

Peginterferon 2a/Ribavirin FDA Antiviral Drugs Advisory Committee

Peginterferon 2a/Ribavirin FDA Antiviral Drugs Advisory Committee. Brian Murphy, MD, MPH, MS InterMune Submitted November 12, 2002 for Presentation November 14, 2002. Disclosure. Presently serve as Vice-President Corporate Development/Hepatology at InterMune

433 views • 13 slides

FDA Advisory Committee January 13, 2003

FDA Advisory Committee January 13, 2003. Genzyme Marketing Application STN 103979 / 0 Recombinant human  -Galactosidase For Treatment of Fabry Disease. Agalsidase beta: Proposed indication and dose. Proposed indication: “..indicated for use as a long-term enzyme replacement..”

807 views • 63 slides

Psychopharmacologic Drugs Advisory Committee June 16, 2003

Psychopharmacologic Drugs Advisory Committee June 16, 2003. Tarek A. Hammad, MD, PhD, MSc, MS Medical Reviewer Division of Neuropharmacological Drug Products Center for Drug Evaluation and Research, FDA. 1. Outline. Generic Drugs Registry Data Are We Seeing the Full Picture?

306 views • 17 slides

More Related

Development of Drugs for Resistant Organisms Presentation to FDA Anti-Infective Drugs Advisory Committee March 5, 2003

Development of Drugs for Resistant Organisms Presentation to FDA Anti-Infective Drugs Advisory Committee March 5, 2003

Presentation Transcript

FDA Oncologic Drugs Advisory Committee Pediatric Oncology Subcommittee

FDA Medical Imaging Drugs Advisory Committee

Anti-Infective Drugs Advisory Committee Meeting Clinical Trial Designs for Community Acquired Pneumonia

Arthritis Advisory Committee March 5, 2003

DOSE SELECTION FOR ANTI-INFECTIVE DRUGS: INDUSTRY PERSPECTIVE

FDA Anesthetic &amp; Life Support Drugs Advisory Committee Sept. 10, 2003

Anti-infective Drugs

Update on Congenital Eye Malformations Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting J

Presented by Carl Norden, M.D. at the Anti-Infective Drugs Advisory Committee meeting on October 28, 2003

III.6. Anti-infective Drugs

FDA Anti-Infective Drugs Advisory Committee, October 2003

Joint Meeting of the Anti-Infective Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee

FDA Advisory Committee March 6, 2003

Antiviral Drugs Advisory Committee Meeting

Ant-Infective Drugs

Presented by Carl Norden, M.D. at the Anti-Infective Drugs Advisory Committee

FDA Endocrine and Metabolic Drugs Advisory Committee October 7, 2003

FDA Advisory Committee for Pharmaceutical Science—March 13, 2003

Development of Drugs for Resistant Pathogens

Peginterferon 2a/Ribavirin FDA Antiviral Drugs Advisory Committee

FDA Advisory Committee January 13, 2003

Psychopharmacologic Drugs Advisory Committee June 16, 2003

FDA Anesthetic & Life Support Drugs Advisory Committee Sept. 10, 2003